Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99


Any time

2020 ( 1 )

2019 ( 32 )

2018 ( 362 )

2017 ( 380 )

Custom range...

Search Results: 1 - 10 of 25998 matches for " Hui-Kyung Jeon "
All listed articles are free for downloading (OA Articles)
Page 1 /25998
Display every page Item
Evolution of a black hole at the center of GRB
Hyun Kyu Lee,Hui-Kyung Kim
Physics , 2002,
Abstract: Using a simplified model of a black hole-accretion disk system which is dominated by Poynting flux, the evolution of the central black hole which is supposed to be powering GRB is discussed. It is demonstrated explicitly that there is a lower limit on the angular momentum parameter for a given GRB energy. It is found that the most energetic GRBs can only accommodate relatively rapid-rotating black holes at the center. For a set of GRBs for which the isotropic energies and T_90s are known, the effect of the disk mass and the magnetic field on the horizon are discussed quantitatively. It is found that the magnetic field has little influence on the energy but affects the GRB duration as expected. The role of the disk mass is found to be significant in determining both the energy and the duration.
Evolution of a Rotating Black Hole with a Magnetized Accretion Disk
Hyun Kyu Lee,Hui-Kyung Kim
Physics , 2000,
Abstract: The effect of an accretion disk on the Blandford-Znajek process and the evolution of a black hole are discussed using a simplified system for the black hole - accretion disk in which the accretion rate is supposed to be dominated by the strong magnetic field on the disk. The evolutions of the mass and the angular momentum of the black hole are formulated and discussed with numerical calculations.
Efficacies of the new Paclitaxel-eluting Coroflex Please? Stent in percutaneous coronary intervention; comparison of efficacy between Coroflex Please? and Taxus? (ECO-PLEASANT) trial: study rationale and design
Jae-Bin Seo, Hui-Kyung Jeon, Kyung-Woo Park, Jong-Seon Park, Jang-Ho Bae, Sang-Wook Kim, Keon-Woong Moon, Jae-Woong Choi, Sang-Gon Lee, Woo-Young Chung, Tae-Jin Youn, Soo-Joong Kim, Doo-Il Kim, Byung-Ok Kim, Min-Su Hyon, Keum-Soo Park, Tae-Joon Cha, Hweung-Kon Hwang, Seung-Ho Hur, Hyo-Soo Kim
Trials , 2009, DOI: 10.1186/1745-6215-10-98
Abstract: In the comparison of Efficacy between COroflex PLEASe? ANd Taxus? stent(ECO-PLEASANT) trial, approximately 900 patients are being prospectively and randomly assigned to the either type of Coroflex Please? stent and Taxus Liberte? stent via web-based randomization. The primary endpoint is clinically driven target vessel revascularization at 9 months. The secondary endpoints include major cardiac adverse events, target vessel failure, stent thrombosis and angiographic efficacy endpoints.The ECO-PLEASANT trial is the study not yet performed to directly compare the efficacy and safety of the Coroflex Please? versus Taxus Liberte? stent. On the basis of this trial, we will be able to find out whether the Coroflex Please? stent is non-inferior to Taxus Liberte? stent or not.ClinicalTrials.gov number, NCT00699543.Previous randomized trials have shown the efficacy of a slow-release polymeric sirolimus-eluting stent (Cypher?, Cordis, Warren, NJ, USA), paclitaxel-eluting stent (Taxus?, Boston Scientific, Natick, MA, USA), and zotarolimus-eluting stent (Endeavor?, Medtronic, Minneapolis, MN, USA) over bare metal stents in reducing neointimal hyperplasia, late luminal loss, and angiographic restenosis leading to decreased target lesion revascularization [1-11] The Paclitaxel-eluting Coroflex Please? stent is a newly developed drug eluting stent using the Coroflex? stent platform combined with the drug paclitaxel contained in a polymer coating[12]In the PECOPS I, which was one-arm observational study, the results of Coroflex Please? stent were within the range of other Paclitaxel-eluting coronary stents [12,13] Compared with binary restenosis rate of 7.9% in Taxus IV trial, Coroflex? Please stent showed 7.8% of restenosis rate[7] The 3.1% of 30 day MACE rate is within the range of other trials with stents eluting Paclitaxel or Sirolimus. The 6 month MACE rates in PECOPS I were 8.0%, which was similar to 7.8%, and 8.5% in Taxus II MR and SR, respectively[6] In Taxus IV, 9 month f
Chemerin and Adiponectin Contribute Reciprocally to Metabolic Syndrome
Sang Hui Chu, Mi Kyung Lee, Ki Yong Ahn, Jee-Aee Im, Min Soo Park, Duk-Chul Lee, Justin Y. Jeon, Ji Won Lee
PLOS ONE , 2012, DOI: 10.1371/journal.pone.0034710
Abstract: Obesity and metabolic syndrome (MetS) are considered chronic inflammatory states. Chemerin, a novel adipokine, may play an important role in linking MetS and inflammation. We investigated the association of chemerin with inflammatory markers and with characteristics of MetS in apparently healthy overweight and obese adults. We studied 92 adults; 59 men and 33 women whose average body mass index (BMI) was 28.15±5.08 kg/m2. Anthropometric parameters, insulin resistance indices, lipid profiles, and inflammatory markers including high sensitivity C-reactive protein (hsCRP), pentraxin 3 (PTX3), adiponectin, and chemerin were measured. Controlling for age, gender, and BMI, serum chemerin level was positively correlated with body fat and serum triglyceride, and negatively correlated with adiponectin and high density lipoprotein cholesterol (HDL- C), and was not correlated with altered hsCRP or PTX3 levels. Among the low, moderate and high chemerin groups, high chemerin individuals are more likely to have lower HDL-C. Conversely, individuals in the low adiponectin group are more likely to have lower HDL-C and show more MetS phenotypic traits than moderate and high adiponectin subjects. To determine the relationships of chemerin and adiponectin to MetS and its components, participants were stratified into four groups based on their chemerin and adiponectin levels (high chemerin/high adiponectin, high chemerin/low adiponectin, low chemerin/high adiponectin, or low chemerin/low adiponectin). Participants who were in the high chemerin/low adiponectin group more likely to have dyslipidemia and MetS (OR: 5.79, 95% CI:1.00–33.70) compared to the other three group. Our findings suggest that chemerin and adiponectin may reciprocally participate in the development of MetS.
Mutational Analysis of EYA1, SIX1 and SIX5 Genes and Strategies for Management of Hearing Loss in Patients with BOR/BO Syndrome
Mee Hyun Song, Tae-Jun Kwon, Hui Ram Kim, Ju Hyun Jeon, Jeong-In Baek, Won-Sang Lee, Un-Kyung Kim, Jae Young Choi
PLOS ONE , 2013, DOI: 10.1371/journal.pone.0067236
Abstract: Background Branchio-oto-renal (BOR) or branchio-otic (BO) syndrome is one of the most common forms of autosomal dominant syndromic hearing loss. Mutations in EYA1, SIX1 and SIX5 genes have been associated with BOR syndrome. In this study, clinical and genetic analyses were performed in patients with BOR/BO syndrome focusing on auditory manifestations and rehabilitation. Methods The audiologic manifestations were reviewed in 10 patients with BOR/BO syndrome. The operative findings and hearing outcome were analyzed in patients who underwent middle ear surgeries. The modality and outcome of auditory rehabilitation were evaluated. Genetic analysis was performed for EYA1, SIX1, and SIX5 genes. Results All patients presented with mixed hearing loss. Five patients underwent middle ear surgeries without successful hearing gain. Cochlear implantation performed in two patients resulted in significant hearing improvement. Genetic analysis revealed four novel EYA1 mutations and a large deletion encompassing the EYA1 gene. Conclusions Auditory rehabilitation in BOR/BO syndrome should be individually tailored keeping in mind the high failure rate after middle ear surgeries. Successful outcome can be expected with cochlear implantations in patients with BOR/BO syndrome who cannot benefit from hearing aids. The novel EYA1 mutations may add to the genotypic and phenotypic spectrum of BOR syndrome in the East Asian population.
Impact of Diabetes on Oncologic Outcome of Colorectal Cancer Patients: Colon vs. Rectal Cancer
Justin Y. Jeon, Duck Hyoun Jeong, Min Geun Park, Ji-Won Lee, Sang Hui Chu, Ji-Hye Park, Mi Kyung Lee, Kaori Sato, Jennifer A. Ligibel, Jeffrey A. Meyerhardt, Nam Kyu Kim
PLOS ONE , 2013, DOI: 10.1371/journal.pone.0055196
Abstract: Background To evaluate the impact of diabetes on outcomes in colorectal cancer patients and to examine whether this association varies by the location of tumor (colon vs. rectum). Patients and methods This study includes 4,131 stage I-III colorectal cancer patients, treated between 1995 and 2007 (12.5% diabetic, 53% colon, 47% rectal) in South Korea. Cox proportional hazards modeling was used to determine the prognostic influence of DM on survival endpoints. Results Colorectal cancer patients with DM had significantly worse disease-free survival (DFS) [hazard ratio (HR) 1.17, 95% confidence interval (CI): 1.00–1.37] compared with patients without DM. When considering colon and rectal cancer independently, DM was significantly associated with worse overall survival (OS) (HR: 1.46, 95% CI: 1.11–1.92), DFS (HR: 1.45, 95% CI: 1.15–1.84) and recurrence-free survival (RFS) (HR: 1.32, 95% CI: 0.98–1.76) in colon cancer patients. No association for OS, DFS or RFS was observed in rectal cancer patients. There was significant interaction of location of tumor (colon vs. rectal cancer) with DM on OS (P = 0.009) and DFS (P = 0.007). Conclusions This study suggests that DM negatively impacts survival outcomes of patients with colon cancer but not rectal cancer.
Kyung HS,Micic ID,Jeon IH
Acta Facultatis Medicae Naissensis , 2006,
Abstract: With the advance of arthroscopic surgical technique and instruments, minimal invasive arthroscopic reconstruction has become preferred treatment method for Bankart reconstruction. The aim of this study was to describe surgical technique and report the results after either open or arthroscopic Bankart shoulder stabilization in a retrospective series with a medium-term follow-up. We performed a retrospective study comprising 43 patients (43 shoulders) with symptomatic, traumatic anterior shoulder instability to compare open versus arthroscopic reconstruction. Twenty eight arthroscopic reconstructions and fifteen open reconstructions were performed using metal suture anchors. All of the patients had the Bankart lesion. Independent observers examined the shoulders at a median follow-up period of 41.1 months (range, 16 to 57) for the arthroscopic group and 68.1 months (range, 51 to 113) for the open group. The recurrence rate was two of 15 (13%) in the open group and 7.1% (2 out of 28) in the arthroscopic group. During the follow-up, the Rowe score was 84.3 points (range, 39 to 100) in the open group compared with 87.3 points (range, 53 to 100 for the Rowe scores, respectively) in the arthroscopic group. Both methods produced stable and well-functioning shoulders in the most of patients with the Bankart lesion. Although the arthroscopic technique can lead to a higher recurrence rate, better results were attained for external rotation of the shoulder in the patients treated with this minimally invasive technique.
Assessment of visual disability using visual evoked potentials
Jeon Jihoon,Oh Seiyul,Kyung Sungeun
BMC Ophthalmology , 2012, DOI: 10.1186/1471-2415-12-36
Abstract: Background The purpose of this study is to validate the use of visual evoked potential (VEP) to objectively quantify visual acuity in normal and amblyopic patients, and determine if it is possible to predict visual acuity in disability assessment to register visual pathway lesions. Methods A retrospective chart review was conducted of patients diagnosed with normal vision, unilateral amblyopia, optic neuritis, and visual disability who visited the university medical center for registration from March 2007 to October 2009. The study included 20 normal subjects (20 right eyes: 10 females, 10 males, ages 9–42 years), 18 unilateral amblyopic patients (18 amblyopic eyes, ages 19–36 years), 19 optic neuritis patients (19 eyes: ages 9–71 years), and 10 patients with visual disability having visual pathway lesions. Amplitude and latencies were analyzed and correlations with visual acuity (logMAR) were derived from 20 normal and 18 amblyopic subjects. Correlation of VEP amplitude and visual acuity (logMAR) of 19 optic neuritis patients confirmed relationships between visual acuity and amplitude. We calculated the objective visual acuity (logMAR) of 16 eyes from 10 patients to diagnose the presence or absence of visual disability using relations derived from 20 normal and 18 amblyopic eyes. Results Linear regression analyses between amplitude of pattern visual evoked potentials and visual acuity (logMAR) of 38 eyes from normal (right eyes) and amblyopic (amblyopic eyes) subjects were significant [y = 0.072x + 1.22, x: VEP amplitude, y: visual acuity (logMAR)]. There were no significant differences between visual acuity prediction values, which substituted amplitude values of 19 eyes with optic neuritis into function. We calculated the objective visual acuity of 16 eyes of 10 patients to diagnose the presence or absence of visual disability using relations of y = 0.072x + 1.22 ( 0.072). This resulted in a prediction reference of visual acuity associated with malingering vs. real disability in a range >5.77 μV. The results could be useful, especially in cases of no obvious pale disc with trauma. Conclusions Visual acuity quantification using absolute value of amplitude in pattern visual evoked potentials was useful in confirming subjective visual acuity for cutoff values >5.77 μV in disability evaluation to discriminate the malingering from real disability.
Tetraethylammonium tris(thiocyanato-κN)[tris(1H-pyrazol-1-yl-κN2)methane]nickelate(II)
Ganna Lyubartseva,Sean Parkin,Uma Prasad Mallik,Hee Kyung Jeon
Acta Crystallographica Section E , 2012, DOI: 10.1107/s1600536812024774
Abstract: The title salt, (C8H20N)[Ni(NCS)3(C10H10N6)], consists of a tetraethylammonium cation and an anion comprising an octahedral NiII atom surrounded by three N atoms from a tripodal tris(pyrazol-1-yl)methane ligand, and three thiocyanate ligands, each bound at the N-atom end. The ligand Ni—N distances range from 2.097 (2) to 2.127 (2) for the tripodal ligand and from 2.045 (2) to 2.075 (2) for the thiocyanate ligands. The dihedral angles between the three pyrazole rings are 59.03 (12), 53.09 (10) and 67.90 (10)°.
The 'Harmonizing Optimal Strategy for Treatment of coronary artery stenosis - sAfety & effectiveneSS of drug-elUting stents & antiplatelet REgimen' (HOST-ASSURE) trial: study protocol for a randomized controlled trial
Kyung Park, Byoung-Eun Park, Si-Hyuck Kang, Jin-Joo Park, Seung-Pyo Lee, Kwang Cha, Jay Rhew, Hui-Kyoung Jeon, Eun Shin, Ju Oh, Myung-Ho Jeong, Sanghyun Kim, Kyung-Kuk Hwang, Jung-Han Yoon, Sung Lee, Tae-Ho Park, Keon Moon, Hyuck-Moon Kwon, In-Ho Chae, Hyo-Soo Kim, On behalf of the HOST investigators
Trials , 2012, DOI: 10.1186/1745-6215-13-29
Abstract: In the 'Harmonizing Optimal Strategy for Treatment of coronary artery stenosis - sAfety & effectiveneSS of drug-elUting stents & antiplatelet REgimen' (HOST-ASSURE) trial, approximately 3,750 patients are being prospectively and randomly assigned in a 2 × 2 factorial design according to the type of stent (PtCr-EES vs CoCr-ZES) and antiplatelet regimen (TAT vs DDAT). The first primary endpoint is target lesion failure at 1 year for the stent comparison, and the second primary endpoint is net clinical outcome at 1 month for comparison of antiplatelet therapy regimen.The HOST-ASSURE trial is the largest study yet performed to directly compare the efficacy and safety of the PtCr-EES versus CoCr-ZES in an 'all-comers' population. In addition, this study will also compare the clinical outcome of TAT versus DDAT for 1-month post PCI.ClincalTrials.gov number NCT01267734.Various second-generation drug-eluting stents (DES) have been developed in the hopes of improving both efficacy and safety compared with first-generation DES. Cumulative evidence is building suggesting that compared with the paclitaxel-eluting stent, the second-generation everolimus-eluting stent (EES; Xience V, Abbott Vascular, Santa Clara, CA, USA, Promus, Boston Scientific, Natick, MA, USA) is more effective and safe [1-3], and compared with the sirolimus-eluting stent, it has similar efficacy with a trend toward better safety [4-6]. The next addition to the second-generation DES market has been the zotarolimus-eluting stent (ZES; Resolute, Medtronic, Minneapolis, MN, USA), which showed equivalent outcome compared with the EES in the RESOLUTE All-Comers randomized trial [7]. Both EES and ZES are based on a cobalt chromium alloy stent. Most recently, a newly developed stent alloy, the platinum chromium alloy, was incorporated with everolimus to create the platinum chromium-based EES (PtCr-EES), the Promus Element stent (Boston Scientific, Natick, MA, USA). There are limited data on the clinical efficacy an
Page 1 /25998
Display every page Item

Copyright © 2008-2017 Open Access Library. All rights reserved.